Nasdaq-listed Anixa Biosciences board approves purchase of Bitcoin as reserve asset
Anixa Biosciences, a Nasdaq-listed company, has approved the purchase of Bitcoin as a reserve asset. The company also reiterated its ongoing stock buyback plan. Amit Kumar, CEO of the company, stated that the decision regarding Bitcoin is another way of prudent financial management and can achieve higher shareholder value. Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin’s Surge: Should You Hold Strong or Shift Investments?
Exploring the Dwindling Altcoin Market Amid Bitcoin's Rapid Ascent: To Hold or Diversify Capital in May?

Bitcoin Reaches New Peak Amidst Higher Liquidity
U.S. Spot Bitcoin ETFs Face $359 Million Outflow
U.S. Brokerage Firms and Government Discuss Stablecoin Integration

Trending news
MoreCrypto prices
More








